Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Durvalumab
DRUG: Trastuzumab deruxtecan
DRUG: Rilvegostomig

Sponsor

AstraZeneca